These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 17558263)

  • 1. Developments in the pharmacotherapy of the overactive bladder.
    Sellers DJ; McKay N
    Curr Opin Urol; 2007 Jul; 17(4):223-30. PubMed ID: 17558263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent developments in the management of detrusor overactivity.
    Kumar V; Templeman L; Chapple CR; Chess-Williams R
    Curr Opin Urol; 2003 Jul; 13(4):285-91. PubMed ID: 12811292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacotherapy of overactive bladder: epidemiology and pathophysiology of overactive bladder.
    Latini JM; Giannantoni A
    Expert Opin Pharmacother; 2011 May; 12(7):1017-27. PubMed ID: 21473706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overactive bladder: an update.
    Hashim H; Abrams P
    Curr Opin Urol; 2007 Jul; 17(4):231-6. PubMed ID: 17558264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical compounds for the treatment of overactive bladder.
    Giannitsas K; Konstantinopoulos A; Patsialas C; Athanasopoulos A; Perimenis P
    Expert Opin Ther Pat; 2009 Feb; 19(2):107-17. PubMed ID: 19441912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of action of botulinum neurotoxins, β3-adrenergic receptor agonists, and PDE5 inhibitors in modulating detrusor function in overactive bladders: ICI-RS 2011.
    Kanai A; Zabbarova I; Oefelein M; Radziszewski P; Ikeda Y; Andersson KE
    Neurourol Urodyn; 2012 Mar; 31(3):300-8. PubMed ID: 22275187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insight into new potential targets for the treatment of overactive bladder and detrusor overactivity.
    Cerruto MA; Asimakopoulos AD; Artibani W; Del Popolo G; La Martina M; Carone R; Finazzi-Agrò E
    Urol Int; 2012; 89(1):1-8. PubMed ID: 22738896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The afferent system and its role in lower urinary tract dysfunction.
    Daly DM; Collins VM; Chapple CR; Grundy D
    Curr Opin Urol; 2011 Jul; 21(4):268-74. PubMed ID: 21537194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving the global management of the neurogenic bladder patient: part II. Future treatment strategies.
    Denys P; Corcos J; Everaert K; Chartier-Kastler E; Fowler C; Kalsi V; Nitti V; Schulte-Baukloh H; Schurch B
    Curr Med Res Opin; 2006 May; 22(5):851-60. PubMed ID: 16709307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current management of overactive bladder.
    Cartwright R; Renganathan A; Cardozo L
    Curr Opin Obstet Gynecol; 2008 Oct; 20(5):489-95. PubMed ID: 18797274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Botulinum toxin for detrusor overactivity and symptoms of overactive bladder: where we are now and where we are going.
    Sahai A; Khan MS; Gregson N; Smith K; Dasgupta P;
    Nat Clin Pract Urol; 2007 Jul; 4(7):379-86. PubMed ID: 17615549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Editorial comment on: histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity.
    Haferkamp A
    Eur Urol; 2008 Jun; 53(6):1253. PubMed ID: 18343561
    [No Abstract]   [Full Text] [Related]  

  • 13. Researching bladder afferents-determining the effects of β(3) -adrenergic receptor agonists and botulinum toxin type-A.
    Kanai A; Wyndaele JJ; Andersson KE; Fry C; Ikeda Y; Zabbarova I; De Wachter S
    Neurourol Urodyn; 2011 Jun; 30(5):684-91. PubMed ID: 21661014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of urinary bladder innervation: TRPV1 and botulinum toxin A.
    Charrua A; Avelino A; Cruz F
    Handb Exp Pharmacol; 2011; (202):345-74. PubMed ID: 21290235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacotherapy of the overactive bladder.
    Andersson KE
    Discov Med; 2009 Oct; 8(42):118-24. PubMed ID: 19833057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence.
    Andersson KE; Chapple CR; Cardozo L; Cruz F; Hashim H; Michel MC; Tannenbaum C; Wein AJ
    Curr Opin Urol; 2009 Jul; 19(4):380-94. PubMed ID: 19448545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimuscarinics and overactive bladder: other mechanism of action.
    Yamaguchi O
    Neurourol Urodyn; 2010; 29(1):112-5. PubMed ID: 19693952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity.
    Apostolidis A; Jacques TS; Freeman A; Kalsi V; Popat R; Gonzales G; Datta SN; Ghazi-Noori S; Elneil S; Dasgupta P; Fowler CJ
    Eur Urol; 2008 Jun; 53(6):1245-53. PubMed ID: 18343564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intradetrusor botulinum toxin injections for neurogenic overactive bladder: are we there yet?
    Lemack GE
    Eur Urol; 2008 Feb; 53(2):240-1. PubMed ID: 17997019
    [No Abstract]   [Full Text] [Related]  

  • 20. Changing treatments for overactive bladder.
    Waine E; Stott M
    Nurs Times; 2008 Oct 14-20; 104(41):45-8. PubMed ID: 18979960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.